Bio-Techne, Fresenius Kabi, Wilson Wolf Form Joint Venture for Cell and Gene Therapy
The new company will work to provide the manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies through individual company products and expertise.
Bio-Techne, Fresenius Kabi, and Wilson Wolf announced on Jan. 21, 2020 that they are forming a new joint venture company focused on supporting researchers and biopharmaceutical companies in the field of cell and gene therapy. The venture has yet to be named.
According to a Bio-Techne press release, the new company will work to provide the manufacturing technologies and processes needed to develop and commercialize new cell and gene therapies through individual company products and expertise. Wilson Wolf will supply the company with its G-Rex technology, platform designed to increase the quantity and quality of immune cells for personalized cell therapies; Bio-Techne will offer up its range of proteins, reagents, media, and gene-editing technologies; and Fresenius Kabi will provide its Lovo cell processing system, which washes, concentrates, and harvests cells at a scale needed to develop and commercialize cell and gene therapies.
Source: Bio-Techne
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
